Literature DB >> 6165759

Experimental allergic encephalomyelitis in Lewis rats: inhibition by bacterial lipopolysaccharides and acquired resistance to reinduction by challenge with myelin basic protein.

S Raziuddin, R F Kibler, D C Morrison.   

Abstract

In 2-mo-old Lewis rats immunized with bacterial lipopolysaccharides (LPS) precomplexed to guinea pig myelin basic protein (BP), the clinical and histologic manifestations of experimental allergic encephalomyelitis (EAE) were diminished compared with BP-treated controls. Similarly, in animals immunized with BP and challenged with BP-LPS at the same time or as long as 5 days after, the immunization with BP also inhibited the disease. That this capacity to reduce the incidence of BP-induced EAE is a unique property of LPS was suggested by the fact that other negatively charged molecules, such as DNA, RNA, and dextran sulphate, were not effective in inhibiting the clinical signs of EAE. After recovery from EAE induced by BP, some animals develop a recurrence of the disease if challenged with BP at appropriate intervals. However, after recovery from mild EAE induced by BP-LPS and after challenges with EAE-initiating BP antigens, secondary EAE was inhibited significantly.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6165759

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  The role of serum factors in the suppression of experimental allergic encephalomyelitis: evidence for immunoregulation by antibody to the encephalitogenic peptide.

Authors:  I A MacPhee; M J Day; D W Mason
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

2.  Resolution of acute inflammation bridges the gap between innate and adaptive immunity.

Authors:  Justine Newson; Melanie Stables; Efthimia Karra; Frederick Arce-Vargas; Sergio Quezada; Madhur Motwani; Matthias Mack; Simon Yona; Tatsiana Audzevich; Derek W Gilroy
Journal:  Blood       Date:  2014-07-08       Impact factor: 22.113

3.  Adjuvant immunotherapy is dependent on inducible nitric oxide synthase.

Authors:  D A Kahn; D C Archer; D P Gold; C J Kelly
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.